Glucosi Baxter

Glucosi Baxter is an intravenous glucose solution supplied as a sterile, aqueous preparation. The product contains glucose as the sole active ingredient and is provided in a parenteral nutrition formulation for intravenous administration. It is marketed in the European Union and requires a prescription. Glucosi Baxter is used to supply an immediate source of carbohydrate energy in clinical settings and can be incorporated into customized infusion regimens for hospitalized patients.

Glucosi Baxter is indicated for several clinical situations where rapid carbohydrate delivery or fluid support is required.

- Treatment of acute hypoglycemia when oral glucose is not feasible. - Component of total parenteral nutrition (TPN) to meet caloric needs. - Fluid replacement in patients unable to tolerate oral or enteral intake. - Support during perioperative periods to maintain blood glucose levels. - Adjunctive therapy for electrolyte-balanced solutions in critical care. - Provision of glucose for patients receiving dialysis who require additional energy substrate.

Adverse reactions to Glucosi Baxter are generally related to the glucose load and the intravenous route.

Common: - Hyperglycemia - Local irritation at the infusion site - Nausea or vomiting - Headache - Mild electrolyte disturbances (e.g., low potassium) - Transient increase in serum triglycerides

Serious: - Severe hyperglycemia leading to osmotic diuresis - Hypersensitivity reactions such as rash, urticaria, or anaphylaxis - Volume overload and pulmonary edema - Metabolic acidosis in patients with impaired renal function - Hyperosmolar hyperglycemic state (HHS) in susceptible individuals - Severe electrolyte imbalance (e.g., hypernatremia)

When prescribing Glucosi Baxter, clinicians should consider patient-specific factors and monitor for potential complications.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Monitor fluid balance to avoid volume overload, especially in heart failure. - Use caution in patients with renal impairment due to reduced glucose clearance. - Evaluate electrolyte status, particularly potassium and sodium, before and during therapy. - Avoid rapid infusion rates that may cause osmotic shifts. - Consider contraindication in patients with known hypersensitivity to glucose solutions. - Document indication and duration of therapy in the medical record.

Glucose solutions can interact with other intravenous agents or affect systemic metabolism.

Avoid: - Co-administration with high-concentration dextrose solutions that may cause precipitation. - Simultaneous infusion of calcium‑containing solutions, which can lead to calcium phosphate precipitation. - Use with insulin infusions without appropriate glucose monitoring, risking hypoglycemia.

Use with caution: - Concurrent administration of diuretics, which may exacerbate electrolyte shifts. - Combination with beta‑adrenergic agonists that can increase glucose production. - Overlap with parenteral lipid emulsions, requiring careful monitoring of triglyceride levels.